News about "Updated data demonstrate Roche?s Alecensa increase"

Updated data demonstrate Roche's Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

Updated data demonstrate Roche's Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO20 Virtual Scientific Programme, on 29 May 2020

Updated Data Demonstrate Roche?s Alecensa Increase | 01/06/2020 | By Darshana 449


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members